Zai Lab (9688) Stock Overview
A biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
9688 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Zai Lab Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.64 |
| 52 Week High | US$35.50 |
| 52 Week Low | US$12.31 |
| Beta | 0.88 |
| 1 Month Change | 0.83% |
| 3 Month Change | 2.38% |
| 1 Year Change | -47.43% |
| 3 Year Change | -41.90% |
| 5 Year Change | n/a |
| Change since IPO | -44.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9688 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -1.1% | 5.0% | 1.7% |
| 1Y | -47.4% | 70.3% | 17.0% |
Return vs Industry: 9688 underperformed the Hong Kong Biotechs industry which returned 73% over the past year.
Return vs Market: 9688 underperformed the Hong Kong Market which returned 16.7% over the past year.
Price Volatility
| 9688 volatility | |
|---|---|
| 9688 Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in HK Market | 14.6% |
| 10% least volatile stocks in HK Market | 3.1% |
Stable Share Price: 9688 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 9688's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 1,784 | Samantha Du | www.zailaboratory.com |
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd.
Zai Lab Limited Fundamentals Summary
| 9688 fundamental statistics | |
|---|---|
| Market cap | HK$16.73b |
| Earnings (TTM) | -HK$1.37b |
| Revenue (TTM) | HK$3.60b |
Is 9688 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9688 income statement (TTM) | |
|---|---|
| Revenue | US$460.16m |
| Cost of Revenue | US$411.99m |
| Gross Profit | US$48.17m |
| Other Expenses | US$223.71m |
| Earnings | -US$175.54m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.57 |
| Gross Margin | 10.47% |
| Net Profit Margin | -38.15% |
| Debt/Equity Ratio | 28.6% |
How did 9688 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/12 08:33 |
| End of Day Share Price | 2026/03/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zai Lab Limited is covered by 32 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rebecca Liang | Bernstein |
| Bo Li | BofA Global Research |
| Louise Chen | Cantor Fitzgerald & Co. |